Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Wu, Qiong ^a   Qin, Shu Kui ^b   Teng, Feng Meng ^a   Chen, Chang Jie ^a   Wang, Rui ^a  

^a BENGBU MEDICAL COLLEGE   (China)

^b Nanjing 81 Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CDC25C PHOSPHATASE; CYCLIN B; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; LOBAPLATIN; PHOSPHATASE; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; CDC25C PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOBUTANE DERIVATIVE; PLATINUM COMPLEX; PROTEIN TYROSINE PHOSPHATASE; TP53 PROTEIN, HUMAN;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL CYCLE; CELL GROWTH; CULTURE TECHNIQUE; DOWN REGULATION; DRUG EFFECT; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CDC2 PROTEIN KINASE; CDC25 PHOSPHATASES; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN B; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLOBUTANES; DOWN-REGULATION; E2F TRANSCRIPTION FACTORS; HUMANS; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 77958578181     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-43     Document Type: Article

References (28)

1. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. J Ferlay HR Shin F Bray D Forman C Mathers DM Parkin, Lyon, France: International Agency for Research on Cancer 2010 http://globocan.iarc.fr
2. Treatment modalities for hepatocellular carcinoma. H Hung, Curr Cancer Drug Targets 2005 5 131 138 10.2174/1568009053202063 15810877
3. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Bruix M Sherman JM Llovet M Beaugrand R Lencioni AK Burroughs E Christensen L Pagliaro M Colombo J Rodés EASL Panel of Experts on HCC, J Hepatol 2001 35 421 430 10.1016/S0168-8278(01)00130-1 11592607
4. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. MB Thomas JP O'Beirne J Furuse AT Chan G Abou-Alfa P Johnson, Ann Surg Oncol 2008 15 1008 1014 10.1245/s10434-007-9705-0 18236117
5. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. S Louafi V Boige M Ducreux L Bonyhay T Mansourbakht T de Baere A Asnacios L Hannoun T Poynard J Taeb, Cancer 2007 109 1384 1390 10.1002/cncr.22532 17330837
6. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. V Boige JL Raoul JP Pignon O Bouché JF Blanc L Dahan JL Jouve N Dupouy M Ducreux Fédération Francophone de Cancérologie Digestive, Br J Cancer 2007 97 862 867 17876335 (Pubitemid 47519302)
7. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients [meeting abstract]. S Qin Y Bai S Ye J Fan H Lim JY Cho S Thongprasert Y Chao K Rau Y Sun, J Clin Oncol 2010 28 4008
8. Lobaplatin: a new antitumour platinum drug. MJ McKeage, Expert Opin Investig Drugs 2001 10 119 128 10.1517/13543784.10.1.119 11116285
9. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. JA Gietema EG de Vries DT Sleijfer PH Willemse HJ Guchelaar DR Uges P Aulenbacher R Voegeli NH Mulder, Br J Cancer 1993 67 396 401 8431374
10. Phase I clinical trial of lobaplatin (D-19466) after intravenous bolus injection. HH Fiebig H Hens K Mross, Onkologie 1994 17 142 148 10.1159/000218399
11. State Food and Drug Administration Database. http://app1.sfda.gov.cn/ datasearch/face3/base.jsp
12. Cyclins and cdks in development and cancer: a perspective. A Deshpande P Sicinski PW Hinds, Oncogene 2005 24 2909 2915 10.1038/sj.onc.1208618 15838524
13. Linking cyclins to transcriptional control. O Coqueret, Gene 2002 299 35 55 10.1016/S0378-1119(02)01055-7 12459251
14. The Rb/E2F pathway: expanding roles and emerging paradigms. JW Harbour DC Dean, Genes Dev 2000 14 2393 2409 10.1101/gad.813200 11018009
15. Inhibitors of mammalian G1 cyclin-dependent kinases. CJ Sherr JM Roberts, Genes Dev 1995 9 1149 1163 10.1101/gad.9.10.1149 7758941
16. Mammalian G1and G2 phase checkpoints. PM O'Connor, Cancer Surv 1997 29 151 182 9338101
17. Universal control mechanism regulating onset of M-phase. P Nurse, Nature 1990 344 503 508 10.1038/344503a0 2138713
18. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinuma nalogue (1R, 2R-diaminocyclohexane)(trans- diacetato)(dichloro)-platinum (IV). GS Hagopian GB Mills AR Khokhar RC Bast Jr ZH Siddik, Clin Cancer Res 1999 5 655 663 10100719
19. CDK inhibitors: positive and negative regulators of G1-phase progression. CJ Sherr JM Roberts, Genes Dev 1999 13 1501 1512 10.1101/gad.13.12.1501 10385618
20. Regulation of the G2/M transition by p53. WR Taylor GR Stark, Oncogene 2001 20 1803 1815 10.1038/sj.onc.1204252 11313928
21. Heavy ion beams induce survivin expression in human hepatoma SMMC-7721 cells more effectively than X-rays. L Gong X Jin Q Li J Liu L An, Acta Biochim Biophys Sin (shanghai) 2007 39 575 582 10.1111/j.1745-7270.2007.00314.x 17687492
22. Gene induction and apoptosis in human hepatocellular carcinoma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine. H Fan ZJ Zhao YC Cheng YF Shan ZH Lu JQ Zhang W Xie, Chin Med J (Engl) 2007 120 1626 1631 17908484
23. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. A Harstrick C Bokemeyer M Schamofkse G Hapke D Reile HJ Schmoll, Cancer Chemother Pharmacol 1993 33 43 47 10.1007/BF00686021 8269588
24. In vitro formation of DNA adducts by cisplatin, lobaplatin, and oxaliplatin in calf thymus DNA in solution and in cultured human cells. CP Saris PJ van de Vaart RC Rietbroek FA Blommaert, Carcinogenesis 1996 17 2763 2769 10.1093/carcin/17.12.2763 9006117
25. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. CM Sorenson A Eastman, Cancer Res 1988 48 6703 6707 3180081
26. The role of apoptosis in cell killing by ciplatin: a flow cytometric study. MG Ormerod RM Orr JH Peacock, Br J Cancer 1994 69 93 100 8286217
27. cis-Diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells. K Nishio Y Fujiwara Y Miyahara Y Takeda T Ohira N Kubota S Ohta Y Funayama H Ogasawara M Ohata, Int J Cancer 1993 55 616 622 10.1002/ijc.2910550417 8406990
28. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. C Voland A Bord A Péleraux G Pénarier D Carrière S Galiègue E Cvitkovic O Jbilo P Casellas, Mol Cancer Ther 2006 5 2149 2157 10.1158/1535-7163.MCT-05-0212 16985047